Business, energy, technology, markets and global industry news from Business News Today

AI drug discovery

PharmaDeviceNews AI drug discovery
Representative image: AI-powered drug discovery research lab illustrating Insilico Medicine and SK Biopharmaceuticals’ $2.5 billion CNS neuroimmune drug development pact.
Pharma & Biotech

Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery

Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.

Read More
Representative image of AI-enabled liver disease research, reflecting how insitro’s CTRO-1013 MASH candidate is being studied for anti-fibrotic signals beyond liver fat reduction.
Pharma & Biotech

insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test

AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.

Read More
Pharma & Biotech

Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?

Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.

Read More
Pharma & Biotech

Can Passkey Therapeutics turn drug combinations into a faster clinical strategy?

AI drug platforms need clinical proof. Passkey’s new CMO must show whether Locksmith-picked combinations can move faster into patients.

Read More
Representative image: Researchers review AI-enabled virtual screening data and molecular models in a drug discovery lab as Concept Life Sciences and OpenBench push a success-based model for faster, lower-risk biotech hit validation.
Pharma & Biotech

Concept Life Sciences expands drug discovery model as OpenBench brings AI-enabled screening scale

Biotechs need faster hits with less upfront risk. Concept Life Sciences and OpenBench are testing whether success-based discovery can deliver.

Read More
Representative image of an AI-enabled biotechnology lab, illustrating how the LenioBio and Twist Bioscience partnership could accelerate protein expression, wet-lab validation, and next-generation AI drug discovery workflows.
Pharma & Biotech

AI can design proteins faster than labs can test them. LenioBio and Twist want to fix that bottleneck

AI can design proteins fast. Biology still sets the pace. LenioBio and Twist Bioscience are targeting drug discovery’s validation gap.

Read More
Pharma & Biotech

Insilico Medicine’s AI-designed anemia therapy begins Phase I testing in collaboration with TaiGen

Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.

Read More
Pharma & Biotech

XtalPi and ReviR Therapeutics push AI-designed RTX-117 into human trials for rare neurological disorders

RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.

Read More
Congruence Revenir platform moves into neurology and immunology under Ono agreement
Pharma & Biotech

Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal

Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.

Read More
Pharma & Biotech

Quiver Bioscience deal shows how Angelini Pharma is rethinking genetic epilepsy innovation

Angelini Pharma partners with Quiver Bioscience to discover new genetic epilepsy targets. Find out what this changes for drug discovery and patients.

Read More